The first human trial to evaluate a candidate vaccine against coronavirus disease 2019 has begun in Seattle, US health officials said on Monday.
“The open-label trial will enrol 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks,” the US National Institutes of Health said in a statement.
“The first participant received the investigational vaccine today.”